Literature DB >> 16041695

BIC and miR-155 are highly expressed in Hodgkin, primary mediastinal and diffuse large B cell lymphomas.

Joost Kluiver1, Sibrand Poppema, Debora de Jong, Tjasso Blokzijl, Geert Harms, Susan Jacobs, Bart-Jan Kroesen, Anke van den Berg.   

Abstract

In a previous study we demonstrated high expression of the non-coding BIC gene in the vast majority of Hodgkin's lymphomas (HLs). Evidence suggesting that BIC is a primary microRNA transcript containing the mature microRNA-155 (miR-155) as part of a RNA hairpin is now accumulating. We therefore analysed HL cell lines and tissue samples to determine whether miR-155 is also expressed in HL. High levels of miR-155 could be demonstrated, indicating that BIC is processed into a microRNA in HL. Most non-HL subtypes were negative for BIC as determined by RNA-ISH. However, in diffuse large B cell lymphoma (DLBCL) and primary mediastinal B cell lymphoma (PMBL), significant percentages of positive tumour cells were observed in 12/18 and 8/8 cases. A higher proportion of tumour cells were positive for BIC in DLBCL with activated B cell-like phenotype than in DLBCL with germinal centre B cell-like phenotype. Differential BIC expression was confirmed by qRT-PCR analysis. Northern blot analysis showed expression of miR-155 in all DLBCL and PMBL derived cell lines and tissue samples analysed. In summary, we demonstrate expression of primary microRNA BIC and its derivative miR-155 in HL, PMBL and DLBCL. Copyright (c) 2005 Pathological Society of Great Britain and Ireland. Published by John Wiley & Sons, Ltd.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16041695     DOI: 10.1002/path.1825

Source DB:  PubMed          Journal:  J Pathol        ISSN: 0022-3417            Impact factor:   7.996


  264 in total

1.  miRNAs in human cancer.

Authors:  Xiaomin Zhong; George Coukos; Lin Zhang
Journal:  Methods Mol Biol       Date:  2012

2.  Regulation of acute graft-versus-host disease by microRNA-155.

Authors:  Parvathi Ranganathan; Catherine E A Heaphy; Stefan Costinean; Nicole Stauffer; Caroline Na; Mehdi Hamadani; Ramasamy Santhanam; Charlene Mao; Patricia A Taylor; Sukhinder Sandhu; Gang He; Arwa Shana'ah; Gerard J Nuovo; Alessandro Lagana; Luciano Cascione; Susanna Obad; Oliver Broom; Sakari Kauppinen; John C Byrd; Michael Caligiuri; Danilo Perrotti; Gregg A Hadley; Guido Marcucci; Steven M Devine; Bruce R Blazar; Carlo M Croce; Ramiro Garzon
Journal:  Blood       Date:  2012-03-09       Impact factor: 22.113

3.  MicroRNAs, macrocontrol: regulation of miRNA processing.

Authors:  Izabella Slezak-Prochazka; Selvi Durmus; Bart-Jan Kroesen; Anke van den Berg
Journal:  RNA       Date:  2010-04-27       Impact factor: 4.942

4.  Transcriptome and targetome analysis in MIR155 expressing cells using RNA-seq.

Authors:  Guorong Xu; Claire Fewell; Christopher Taylor; Nan Deng; Dale Hedges; Xia Wang; Kun Zhang; Michelle Lacey; Haitao Zhang; Qinyan Yin; Jennifer Cameron; Zhen Lin; Dongxiao Zhu; Erik K Flemington
Journal:  RNA       Date:  2010-06-28       Impact factor: 4.942

Review 5.  miRNAs in normal and malignant B cells.

Authors:  Ai Kotani; Ratanakanit Harnprasopwat; Takae Toyoshima; Toyotaka Kawamata; Arinobu Tojo
Journal:  Int J Hematol       Date:  2010-07-08       Impact factor: 2.490

6.  Hodgkin lymphoma cell lines are characterized by a specific miRNA expression profile.

Authors:  Johan H Gibcus; Lu Ping Tan; Geert Harms; Rikst Nynke Schakel; Debora de Jong; Tjasso Blokzijl; Peter Möller; Sibrand Poppema; Bart-Jan Kroesen; Anke van den Berg
Journal:  Neoplasia       Date:  2009-02       Impact factor: 5.715

7.  microRNA expression in the biology, prognosis, and therapy of Waldenström macroglobulinemia.

Authors:  Aldo M Roccaro; Antonio Sacco; Changzhong Chen; Judith Runnels; Xavier Leleu; Feda Azab; Abdel Kareem Azab; Xiaoying Jia; Hai T Ngo; Molly R Melhem; Nicholas Burwick; Lyuba Varticovski; Carl D Novina; Barrett J Rollins; Kenneth C Anderson; Irene M Ghobrial
Journal:  Blood       Date:  2008-12-12       Impact factor: 22.113

Review 8.  The biology of Hodgkin's lymphoma.

Authors:  Ralf Küppers
Journal:  Nat Rev Cancer       Date:  2008-12-11       Impact factor: 60.716

9.  Epstein-Barr virus growth/latency III program alters cellular microRNA expression.

Authors:  Jennifer E Cameron; Claire Fewell; Qinyan Yin; Jane McBride; Xia Wang; Zhen Lin; Erik K Flemington
Journal:  Virology       Date:  2008-10-31       Impact factor: 3.616

Review 10.  MicroRNA in pancreatic cancer: pathological, diagnostic and therapeutic implications.

Authors:  Satyanarayana Rachagani; Sushil Kumar; Surinder K Batra
Journal:  Cancer Lett       Date:  2009-12-09       Impact factor: 8.679

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.